{
    "1623942680450330626": {
        "author_id": "194037150",
        "created_at": "2023-02-10T07:11:21.000Z",
        "edit_history_tweet_ids": [
            "1623942680450330626"
        ],
        "entities": {
            "annotations": [
                {
                    "end": 5,
                    "normalized_text": "PRESS",
                    "probability": 0.4931,
                    "start": 1,
                    "type": "Other"
                },
                {
                    "end": 15,
                    "normalized_text": "Heartseed",
                    "probability": 0.5191,
                    "start": 7,
                    "type": "Other"
                },
                {
                    "end": 32,
                    "normalized_text": "Novo Nordisk",
                    "probability": 0.4912,
                    "start": 21,
                    "type": "Organization"
                },
                {
                    "end": 88,
                    "normalized_text": "HS-",
                    "probability": 0.5183,
                    "start": 86,
                    "type": "Other"
                }
            ],
            "hashtags": [
                {
                    "end": 6,
                    "start": 0,
                    "tag": "PRESS"
                }
            ]
        },
        "id": "1623942680450330626",
        "lang": "en",
        "public_metrics": {
            "bookmark_count": 0,
            "impression_count": 10156,
            "like_count": 58,
            "quote_count": 0,
            "reply_count": 3,
            "retweet_count": 18
        },
        "text": "#PRESS Heartseed and Novo Nordisk announce first patient dosed in clinical study with HS-001 \u2013 a cell therapy designed to restore heart function in people with advanced heart failure"
    }
}